NEW YORK (TheStreet) -- CHANGE IN RATINGS
upgraded at UBS from Neutral to Buy. $13 price target. Valuation call, given the company's low multiple.
upgraded at Credit Suisse to Neutral from Underperform as growth will exceed peers over next few quarters. 2009 and 2010 EPS estimates raised to $1 and $1.15, respectively. Price target lifted by 3 dollars to $31.
rated new Neutral at Goldman. $15 price target. Near-term results could be challenging, but the company should be able to post gradual growth.
upgraded at Janney Montgomery from Neutral to Buy. $45 price target. Stock is down from its highs, but 2010 prospects are improving.
rated new Buy at Citigroup. $66 price target. Company is a leader in subsea equipment, and should be able to capture more large-scale projects in the coming years.
upgraded at Credit Suisse to Outperform from Neutral on order growth and valuation. 2009 and 2010 EPS estimates introduced at -$3.35 and -$0.75, respectively. Price target raised by a dollar to $18.
rated new Overweight at Morgan Stanley. $33 price target. Company should outperform its peers, even though industry pricing should become more competitive in 2011.
upgraded at Credit Suisse to Neutral from Underweight on strong balance sheet and land opportunities. 2009 and 2010 EPS estimates introduced at -$2.85 and -$1.35, respectively. Price target lifted to $29 from $26.
downgraded at Credit Suisse to Neutral from Outperform on valuation. 2009 and 2010 EPS estimates tweaked to $0.95 and $1.32, respectively. Maintain $16 price target.
RF Micro Devices
upgraded at UBS from Neutral to Buy. $5.50 price target. Company paid down debt and cash flow is improving. End-markets also appear to be improving.
upgraded at Credit Suisse to Outperform from Neutral on earlier recovery. 2009 and 2010 EPS estimates set at -$4.52 and -$1.55, respectively. Price target raised to $29 from $23.
downgraded at Goldman from Neutral to Sell. $16 price target. Wine results could fall short of expectations.
rated new Buy at Needham. Coverage of SWI was started with a Buy rating. $24 price target. Company should be able to sustain 25% annual organic sales growth.
upgraded at BB&T from Hold to Buy. $34 price target. Company should be able to exceed near-term expectations.
STOCK COMMENTS / EPS CHANGES
price target raised at Credit Suisse to $55 from $42 as the company is starting recovery. 2010 and 2011 EPS estimates set at $2.68 and $3.06, respectively. Outperform rating.
estimates, target increased at FBR. Shares of AMZN now seen reaching $160. Estimates were also raised, to reflect market share gains. Outperform rating.
added to Top Picks Live list at Citigroup. Estimates also boosted, as the AL packaging deal should create significant value. Buy rating and new $36 price target.
estimates lowered at Morgan Stanley through 2011. Gross margins continue to fall. Equal-weight rating.
estimate cut at Barclays. CVD 2010 EPS estimate lowered to $3.00 from $3.18. Maintain Equal Weight rating and $47 price target.
estimates, target raised at Goldman. Target was increased to $105. Estimates also boosted, to reflect synergies from the NextRx deal. Buy rating.
numbers boosted at FBR. Shares of FCS now seen reaching $16. Estimates also raised, to reflect the company's new guidance. Outperform rating.
price target boosted at Credit Suisse to $26 from $22. 2009 EPS estimate raised to $1.94, 2010 lowered to $1.66. Outperform rating.
numbers raised at UBS. Shares now seen reaching $66. Estimates also boosted, to reflect new government HIV treatment guidelines. Buy rating.
Sirona Dental Systems
target, estimate higher at Barclays. Barclays raised SIRO price target to $30 from $26. 2009 EPS maintained at $1.72, 2010 lifted to $1.92. Equal Weight rating.
target, estimates raised at Credit Suisse. SPLS price target increased to $29 from $26. 2010 EPS estimate raised to $1.13, 2011 maintained at $1.38. Reiterate Outperform rating.
estimates, target raised at Goldman. Shares of SPLS now seen reaching $27. Estimates also boosted, as the company's operating margin appears to have bottomed out. Buy rating.
target boosted at FBR. Shares seen reaching $20. Retail sales are improving and the stock deserves a market multiple. Underperform rating.
estimate lower at Barclays. Barclays trimmed UNH 2010 EPS estimate by 10 cents to $3.15, 2009 maintained at $3.18. Reiterate Overweight rating and $33 price target.
Universal Technical Institute
estimates raised at Credit Suisse. Increased UTI 2009 and 2010 EPS estimates to $0.48 and $0.92, respectively. Maintain Neutral rating and $19 price target.
price target cut at Barclays. XRAY price target lowered by a dollar to $36. Maintain 2009 and 2010 EPS estimates at $1.85 and $2.08, respectively. Overweight rating.
numbers cut at FBR. Shares of ZION now seen reaching $19. Estimates also reduced, to reflect lower expected fee income and a smaller net interest margin. Outperform rating.
This article was written by a staff member of TheStreet.com.